Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.

Cornelison R, Dobbin ZC, Katre AA, Jeong DH, Zhang Y, Chen D, Petrova Y, Llaneza DC, Steg AD, Parsons L, Schneider DA, Landen CN.

Clin Cancer Res. 2017 Nov 1;23(21):6529-6540. doi: 10.1158/1078-0432.CCR-17-0282. Epub 2017 Aug 4.


The presence of primary cilia in cancer cells does not predict responsiveness to modulation of smoothened activity.

Spann AL, Yuan K, Goliwas KF, Steg AD, Kaushik DD, Kwon YJ, Frost AR.

Int J Oncol. 2015 Jul;47(1):269-79. doi: 10.3892/ijo.2015.3006. Epub 2015 May 15.


Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.

Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH, Landen CN.

Oncotarget. 2014 Aug 30;5(16):7065-80.


Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D, Landen CN.

Oncotarget. 2014 Sep 30;5(18):8750-64.


Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN.

Clin Cancer Res. 2013 Jan 1;19(1):170-82. doi: 10.1158/1078-0432.CCR-12-1045. Epub 2012 Nov 12.


Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer.

Grunda JM, Steg AD, He Q, Steciuk MR, Byan-Parker S, Johnson MR, Grizzle WE.

BMC Res Notes. 2012 May 22;5:248. doi: 10.1186/1756-0500-5-248.


Smoothened antagonists reverse taxane resistance in ovarian cancer.

Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD, Landen CN.

Mol Cancer Ther. 2012 Jul;11(7):1587-97. doi: 10.1158/1535-7163.MCT-11-1058. Epub 2012 May 2.


Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.


Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN.

Clin Cancer Res. 2011 Sep 1;17(17):5674-85. doi: 10.1158/1078-0432.CCR-11-0432. Epub 2011 Jul 13.


Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERĪ± negative breast cancer cell lines.

Kwon YJ, Hurst DR, Steg AD, Yuan K, Vaidya KS, Welch DR, Frost AR.

Clin Exp Metastasis. 2011 Jun;28(5):437-49. doi: 10.1007/s10585-011-9382-z. Epub 2011 Mar 27.


Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.

Amm HM, Zhou T, Steg AD, Kuo H, Li Y, Buchsbaum DJ.

Mol Cancer Res. 2011 Apr;9(4):403-17. doi: 10.1158/1541-7786.MCR-10-0133. Epub 2011 Feb 25.


Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.

Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2010 Dec;9(12):3186-99. doi: 10.1158/1535-7163.MCT-10-0563. Epub 2010 Oct 1.


Primary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissues.

Yuan K, Frolova N, Xie Y, Wang D, Cook L, Kwon YJ, Steg AD, Serra R, Frost AR.

J Histochem Cytochem. 2010 Oct;58(10):857-70. doi: 10.1369/jhc.2010.955856. Epub 2010 Jun 7.


Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer.

Xu L, Kwon YJ, Frolova N, Steg AD, Yuan K, Johnson MR, Grizzle WE, Desmond RA, Frost AR.

Breast Cancer Res Treat. 2010 Aug;123(1):59-71. doi: 10.1007/s10549-009-0617-5. Epub 2009 Nov 10.

Supplemental Content

Support Center